The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Comments Comments
  •  (1)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

Fight for Cheap Drugs Shifts From AIDS to New Hepatitis Pills

December 17, 2013

This article was reported by Fox News.

Fox News reported that the recent approval of the hepatitis C virus (HCV) treatment Sovaldi would trigger an international battle for low-cost access, similar to earlier disputes over access to generic HIV/AIDS drugs. Manufacturer Gilead Sciences priced Sovaldi at $1,000 per day. Experts expect the drug to transform treatment because some HCV patients would be able to take a single Sovaldi pill daily, eliminating the need for interferon injections, which could cause severe flu-like symptoms. At current prices, Sovaldi treatment would cost $84,000 for a 12-week regimen.

View Full Article

Related Stories

FDA Approves Sovaldi (Sofosbuvir) for Chronic Hepatitis C
The Cure for Hepatitis C, Withheld
Activists Condemn Gilead for Exorbitant Price of Their New Hepatitis C Drug
Talk to a Physician About HIV/Hepatitis Coinfection in Our "Ask the Experts" Forums
More News on Hepatitis C Treatment

  • Email Email
  • Comments Comments
  •  (1)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary


Reader Comments:

Comment by: Amanda R (Pasadena, Tx) Tue., Jul. 29, 2014 at 11:13 am EDT
This drug that can cure hepatitis c should be made affordable to all who are infected. There is absolutely no reason the lower income infected should suffer due to obscene costs for a medicine that could cure so many!
Reply to this comment

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining: